Mereo BioPharma gets investment of $3 Million

Mereo BioPharma has entered into a Securities Purchase Agreement with a new U.S.-based institutional healthcare investor. Under the terms of the Agreement, the institutional investor has agreed to make an investment of $3 million to purchase 12,252,715 of the Company’s ordinary shares (equivalent to 2,450,543 American Depository shares (ADSs)) at a price equivalent to 18.8 pence per share, which represents a 20% discount over Mereo’s closing share price of 23.5 pence on AIM on February 18, 2020.

Read more

Mereo to present its osteogenesis imperfecta study data in Orlando

Mereo BioPharma will present the 6-month interim data from the open label arm of the its Phase 2b dose-ranging clinical study of setrusumab (BPS-804) in adults with Type I, III or IV osteogenesis imperfecta (OI) at the upcoming American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting to be held from September 20-23 in Orlando, FL.

Read more